<DOC>
	<DOC>NCT01303744</DOC>
	<brief_summary>To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.</brief_summary>
	<brief_title>Evaluation of Safety &amp; Tolerability of Multiple Dose Regimens of CHF 5074</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of amnestic or nonamnestic Mild Cognitive Impairment. MiniMental State Examination score higher than 24 at screening. MRI scan of the brain at screening with fluidattenuation inversion recovery (FLAIR) and T2*weighted gradientrecalledecho (GRE) sequences. Diagnosis of Alzheimer's disease according to the (DSMIVTR) or NINCDSADRDA criteria. Any medical condition that could explain the patients cognitive deficits. CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter â‰¤ 10 mm). Geriatric Depression Scale (30point scale) score &gt; 9 at screening. History of stroke. Modified Hachinski ischemic scale score &gt; 4 at screening. Women of childbearing potential. Vitamin B12 or folate deficiency. Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening. Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease. Concomitant use of donepezil at doses &gt; 5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose. Concomitant use of memantine at dose &gt; 20 mg/day. Concomitant use of psychoactive drugs (sedatives, hypnotics, etc).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>